Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR12075(B)] to TAF9 (HRP)
- Suitable for: WB
- Reacts with: Human
- Conjugation: HRP
Product nameAnti-TAF9 antibody [EPR12075(B)] (HRP)
See all TAF9 primary antibodies
DescriptionRabbit monoclonal [EPR12075(B)] to TAF9 (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Cow, Orangutan
Synthetic peptide within Human TAF9 aa 50-150. The exact sequence is proprietary.
Database link: Q16594
- WB: K562 whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: PBS, 30% Glycerol, 1% BSA
Concentration information loading...
PurityProtein A purified
- HeLa nuclear extract lysate (ab14655)
- K562 nuclear extract lysate (ab14851)
- MCF7 nuclear extract lysate (ab14860)
- HeLa whole cell lysate (ab150035)
- HeLa nuclear extract lysate (ab150036)
- HeLa whole cell lysate (ab29545)
- MCF7 whole cell lysate (ab3871)
- A431 whole cell lysate (ab7909)
- K562 whole cell lysate (ab7911)
Our Abpromise guarantee covers the use of ab209310 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 29 kDa (predicted molecular weight: 29 kDa).|
RelevanceTAF9 functions as a component of the DNA-binding general transcription factor complex TFIID and the regulatory transcription complex SAGA. Binding of TFIID to a promoter (with or without TATA element) is the initial step in pre-initiation complex (PIC) formation. TFIID plays a key role in the regulation of gene expression by RNA polymerase II through different activities such as transcription activator interaction, core promoter recognition and selectivity, TFIIA and TFIIB interaction, chromatin modification (histone acetylation by TAF1), facilitation of DNA opening and initiation of transcription. SAGA influences RNA polymerase II transcriptional activity through different activities such as TBP interaction (SPT3 and SPT8) and promoter selectivity, interaction with transcription activators (GCN5, ADA2, ADA3, and TRA1), and chromatin modification through histone acetylation (GCN5).
- TAF9 RNA polymerase II, TATA box-binding protein-associated factor, 32kDa antibody
- MGC:1603 antibody
- MGC:3647 antibody
Anti-TAF9 antibody [EPR12075(B)] (HRP) (ab209310) at 1/5000 dilution + K562 (Human erythromyeloblastoid leukemia cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 29 kDa
Observed band size: 29 kDa
Exposure time: 3 minutes
This blot was produced using a 4-12% Bis-tris gel under the MES buffer system. The gel was run at 200V for 35 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab209310 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab209310 has not yet been referenced specifically in any publications.